MedGadget Editorial Team - MedGadget

Overlapping circles graphic showing Biomapas and Pinnaxis combining regulatory and drug safety technology services

Biomapas Acquires Pinnaxis to Expand Drug Safety Technology and Consulting Capabilities

Biomapas acquires Pinnaxis, a pharmacovigilance technology firm in India and New Jersey, to expand drug safety services. Terms undisclosed.

October 8, 2026

Map graphic: Ofichem sites in Ter Apel and Uppsala linked to Kinentia Biosciences in Rensselaer, New York

Pharmaceutical

Ofichem to Acquire Kinentia Biosciences to Expand Drug Substance CDMO Business in US

Ofichem agrees to acquire New York CDMO Kinentia Biosciences, adding a US drug substance site to its Dutch and Swedish network. Terms undisclosed.

October 8, 2026

Infographic: solengepras 150 mg cut Parkinson’s OFF time by 0.61 hours versus placebo in Phase 3 ARISE trial

Pharmaceutical

Cerevance Reports Positive Phase 3 Results for Solengepras in Parkinson’s Disease

Cerevance says Phase 3 ARISE met its primary endpoint: solengepras cut daily OFF time by 0.61 hours versus placebo in Parkinson’s patients.

October 8, 2026

Actor Nana Patekar in 2025, with headline: Nana Patekar, actor of Parinda and Krantiveer, dies at 75

Healthcare Services

Nana Patekar, Celebrated Actor of Parinda and Krantiveer, Dies at 75 in Goa

Nana Patekar dies at 75 after a cardiac emergency in Goa. Career highlights, what is known, why a post-mortem matters and heart-attack warning signs.

October 8, 2026

MedGadget.org banner: Beactica selects BEA-28 TEAD degrader as preclinical candidate for solid tumours

Pharmaceutical

Beactica Therapeutics Selects BEA-28 as Preclinical Candidate for Solid Tumours

Beactica selects BEA-28, a first-in-class TEAD degrader, for solid tumours, with data on KRAS inhibitor resistance. See the risks and next steps.

October 7, 2026

MedGadget.org banner: Italfarmaco and VeriSIM Life partner on HDAC-targeted therapies

Pharmaceutical

Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeted Therapies

Italfarmaco and VeriSIM Life partner on AI-driven HDAC-targeted therapies for neuromuscular, fibrotic and rare diseases in a deal worth over $100M.

October 7, 2026

Pharmaceutical

Lundbeck Reports Phase Ib Results for Lu AF28996 in Advanced Parkinson’s Disease

Lundbeck reports Phase Ib data for Lu AF28996 in advanced Parkinson’s: ON-time up 3.6 hours a day. What the open-label results mean and what Phase II will test.

October 7, 2026

MedGadget.org banner: Piramal opens new microbiology laboratory at its Kentucky sterile injectables site

Pharmaceutical

Piramal Pharma Solutions Opens New Microbiology Laboratory at Kentucky Sterile Injectables Facility

Piramal Pharma Solutions opens a new microbiology laboratory in Lexington, Kentucky, tripling test space and targeting up to 50% faster testing.

October 7, 2026

MedGadget.org banner: RougeTx raises 58 million dollars Series A for oral HHT therapy RTX-001

Pharmaceutical

RougeTx Launches with $58 Million Series A to Advance HHT Therapy RTX-001

RougeTx launches with a $58M Series A to take oral HHT therapy RTX-001 toward the clinic. Investors, how it works and what comes next.

October 7, 2026

Medical Device

UK Introduces Continuous Monitoring Framework for AI Medical Devices in Major Regulatory Shift

The UK accepts all 44 recommendations on AI regulation, moving to lifecycle monitoring of AI medical devices. What the MHRA plans, and when.

October 6, 2026